Overview
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
Description
A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks
Eligibility
Inclusion Criteria:
- Male or female adult ≥ 18 years of age;
- Diagnosis of chronic plaque-type
- Psoriasis affecting 2%-10% BSA
- Patient is being treated with biologic therapy for a minimum of 24 weeks
- Able and willing to give written informed consent prior to performance of any study-related procedures
Exclusion Criteria:
- Psoriasis affecting ˂2% or >10% BSA
- Patient not receiving a biologic agent, or receiving biologic agent <24weeks
- Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit.
- Has previously used DUOBRII